PFM Health Sciences’s Neurocrine Biosciences NBIX Stock Holding History

PFM Health Sciences’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28.4M	Buy	215,678 +52,481	+32%	+$6.96M	2.59%	9
2025 Q4	$23.1M	Buy	163,197 +105,951	+185%	+$15.3M	2.31%	10
2025 Q3	$8.04M	Buy	57,246 +44,425	+347%	+$6.02M	0.62%	44
2025 Q2	$1.61M	Buy	+12,821	New	+$1.47M	0.14%	52
2025 Q1	–	Sell	-166,803	Closed	-$22.8M	–	83
2024 Q4	$22.8M	Buy	+166,803	New	+$20.6M	1.41%	22
2022 Q1	–	Sell	-394,058	Closed	-$33.6M	–	73
2021 Q4	$33.6M	Sell	394,058 -470,021	-54%	-$43.2M	1.14%	40
2021 Q3	$82.9M	Sell	864,079 -251,925	-23%	-$23.8M	2.44%	13
2021 Q2	$109M	Buy	1,116,004 +60,494	+6%	+$5.8M	3.4%	5
2021 Q1	$103M	Buy	+1,055,510	New	+$111M	3.13%	5

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PFM Health Sciences's NBIX Position: Q1 2026 in Review

PFM Health Sciences increased its Neurocrine Biosciences (NBIX) stake by 32% in Q1 2026, buying an estimated $6.96M and bringing the position to 215,678 shares worth $28.4M. The position accounts for 2.59% of the portfolio, ranked #9.

PFM Health Sciences first reported a position in NBIX in Q1 2021 and has held it in 9 quarters since. The position peaked at $109M in Q2 2021. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

PFM Health Sciences held 215,678 shares of Neurocrine Biosciences worth $28.4M as of Q1 2026.
PFM Health Sciences bought 52,481 Neurocrine Biosciences shares in Q1 2026, an estimated $6.96M.
Neurocrine Biosciences made up 2.59% of PFM Health Sciences's portfolio in Q1 2026, its #9 holding.
PFM Health Sciences first reported a position in Neurocrine Biosciences in Q1 2021 and has held it in 9 quarters since.
PFM Health Sciences's Neurocrine Biosciences position peaked at $109M in Q2 2021.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.